In a key step for psychedelic research, magic mushroom compound clears first clinical safety hurdle

In a key step for psychedelic research, magic mushroom compound clears first clinical safety hurdle

Source: 
Endpoints
snippet: 

Exasperated with the often-ineffective existing slate of antidepressants, COMPASS Pathways set up shop in London 2016 — and made a beeline for psilocybin, the psychoactive ingredient in magic mushrooms.